Of interest, it has been shown that thrombomodulin (THBD) was increased in both the lesion and plasma of CCM patients and is being tested as a potential biomarker for hemorrhagic risk in CCMs [37, 44]. Here, THBD is linked to cerebral cavernous malformation.